drugset
Drugs / Rituximab and Hyaluronidase Human
last change May 2024 re-read 3 minutes ago

Rituximab and Hyaluronidase Human

Monoclonal antibody

Developed for
follicular lymphoma · marginal zone lymphoma
Investigated by
Genentech, Inc. · Thomas Jefferson University

Trials 1

today NCT04447716 · Ph 1
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04447716 Oct 2020 → May 2024 overdue follicular lymphoma, marginal zone lymphoma Thomas Jefferson University Active not recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2017-06-22 Genentech, Inc. FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers gene.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Rituximab and Hyaluronidase Human ClinicalTrials.gov intervention name — accepted as the source's own label NCT04447716 ↗
Modality Monoclonal antibody “Immunotherapy with monoclonal antibodies, such as rituximab and rituximab hyaluronidase” NCT04447716 ↗
Route Subcutaneous “rituximab hyaluronidase (if no significant infusion reaction to rituximab) subcutaneously (SC)” NCT04447716 ↗